|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EH04
|
|
gptkbp:brand
|
Nerlynx
|
|
gptkbp:CASNumber
|
698387-09-6
|
|
gptkbp:chemicalFormula
|
C30H29ClN6O3
|
|
gptkbp:contraindication
|
hypersensitivity to neratinib
|
|
gptkbp:developer
|
Puma Biotechnology
|
|
gptkbp:drugInteraction
|
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:eliminationHalfLife
|
7-17 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible inhibitor of HER2 and EGFR
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
557.04 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
fatigue
|
|
gptkbp:synonym
|
HKI-272
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:bfsParent
|
gptkb:P42338
gptkb:protein_tyrosine_kinases
gptkb:HER2/neu_receptor
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
neratinib
|